title: The antitumor immunity of ipilimumab: (T-cell) memories to last a lifetime?
abstract: Ipilimumab has shown an overall survival benefit in 2 randomized phase III studies. A minority of patients achieve long-term disease control, highlighting the potential of this immunotherapeutic approach. In ongoing efforts, investigators are continuing to characterize these patients' unique clinical courses and correlate their responses with underlying mechanisms of antitumor immunity.
authors.affiliation: Department of Medicine and Immunology Program, Ludwig Center for Cancer Immunotherapy, Memorial Sloan-Kettering Cancer CenterNew York, NY 10065, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Postow
authors.forename: Margaret K
authors.initials: MK
authors.lastname: Callahan
authors.forename: Jedd D
authors.initials: JD
authors.lastname: Wolchok
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors*; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; D000074324:Ipilimumab